Jevtana: Global Drug Analysis 2017 with Sales Forecasts to 2026 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Analysis: Jevtana" drug pipelines has been added to ResearchAndMarkets.com's offering.

Jevtana (cabazitaxel; Sanofi) is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing treatment regimen.

By promoting tubulin assembly into microtubules while simultaneously preventing disassembly, Jevtana inhibits mitotic and interphase cellular functions, non-specifically inhibiting cell replication.

Key Topics Covered:

Product Profiles

Jevtana: Prostate cancer

List of Figures

Figure 1: Jevtana for prostate cancer - SWOT analysis

Figure 2: Drug assessment summary of Jevtana for prostate cancer (1)

Figure 3: Drug assessment summary of Jevtana for prostate cancer (2)

Figure 4: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Jevtana drug profile

Table 2: Jevtana pivotal Phase III data in prostate cancer

Table 3: Jevtana Phase III data in prostate cancer

Table 4: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/vxgw7r/jevtana_global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Prostate Cancer Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Prostate Cancer Drugs